Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Phase 3positiveCamizestrantPositive

AI Analysis

Summary

Camizestrant combination demonstrated positive efficacy in the SERENA-6 Phase 3 trial, delaying time to first progression by 55% and time to second progression by 37% in patients with advanced HR-positive breast cancer harboring emergent ESR1 tumor mutations.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Camizestrant combination delayed time to first progression by 55% and time to second progression by 37% in patients with advanced HR-positive breast cancer with emergent ESR1 tumor mutation

Importance:7/10

Sentiment:

0.80

Phase 3 databreast cancerESR1 mutationprogression-free survivalSERENA-6

Related Companies

$AZN

Read the original article

Published by yahoo_finance on June 2, 2026 12:00 PM

Read Original